Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications

Lara L. Chappell, Kim A. Deal, Ekaterina Dadachova, Martin W. Brechbiel

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

225Ac (t(1/2) = 10 days) is an alternative α-emitter that has been proposed for radioimmunotherapy (RIT) due to its many favorable properties, such as half-life and mode of decay. The factor limiting use of 225Ac in RIT is the lack of an acceptably stable chelate for in vivo applications. Herein is described the first reported bifunctional chelate for 225Ac that has been evaluated for stability for in vivo applications. The detailed synthesis of a bifunctional chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10,13,16-hexaazacyclohexadecane- 1,4,7,10,13,16-hexaacetic acid (HEHA-NCS) is reported. This ligand was conjugated to three monoclonal antibodies, CC49, T101, and BL-3 with chelate-to-protein ratios between 1.4 and 2. The three conjugates were radiolabeled with 225Ac, and serum stability study of the [225Ac]-BL-3-HEHA conjugate was performed.

Original languageEnglish (US)
Pages (from-to)510-519
Number of pages10
JournalBioconjugate Chemistry
Volume11
Issue number4
DOIs
StatePublished - Jul 2000
Externally publishedYes

Fingerprint

Radioimmunotherapy
Chelating Agents
Chelation
Monoclonal antibodies
Half-Life
Ligands
Monoclonal Antibodies
Proteins
Acids
Serum

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications. / Chappell, Lara L.; Deal, Kim A.; Dadachova, Ekaterina; Brechbiel, Martin W.

In: Bioconjugate Chemistry, Vol. 11, No. 4, 07.2000, p. 510-519.

Research output: Contribution to journalArticle

Chappell, Lara L. ; Deal, Kim A. ; Dadachova, Ekaterina ; Brechbiel, Martin W. / Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications. In: Bioconjugate Chemistry. 2000 ; Vol. 11, No. 4. pp. 510-519.
@article{558c5b0f875f453f9ad27bed8fd2f315,
title = "Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications",
abstract = "225Ac (t(1/2) = 10 days) is an alternative α-emitter that has been proposed for radioimmunotherapy (RIT) due to its many favorable properties, such as half-life and mode of decay. The factor limiting use of 225Ac in RIT is the lack of an acceptably stable chelate for in vivo applications. Herein is described the first reported bifunctional chelate for 225Ac that has been evaluated for stability for in vivo applications. The detailed synthesis of a bifunctional chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10,13,16-hexaazacyclohexadecane- 1,4,7,10,13,16-hexaacetic acid (HEHA-NCS) is reported. This ligand was conjugated to three monoclonal antibodies, CC49, T101, and BL-3 with chelate-to-protein ratios between 1.4 and 2. The three conjugates were radiolabeled with 225Ac, and serum stability study of the [225Ac]-BL-3-HEHA conjugate was performed.",
author = "Chappell, {Lara L.} and Deal, {Kim A.} and Ekaterina Dadachova and Brechbiel, {Martin W.}",
year = "2000",
month = "7",
doi = "10.1021/bc990153f",
language = "English (US)",
volume = "11",
pages = "510--519",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications

AU - Chappell, Lara L.

AU - Deal, Kim A.

AU - Dadachova, Ekaterina

AU - Brechbiel, Martin W.

PY - 2000/7

Y1 - 2000/7

N2 - 225Ac (t(1/2) = 10 days) is an alternative α-emitter that has been proposed for radioimmunotherapy (RIT) due to its many favorable properties, such as half-life and mode of decay. The factor limiting use of 225Ac in RIT is the lack of an acceptably stable chelate for in vivo applications. Herein is described the first reported bifunctional chelate for 225Ac that has been evaluated for stability for in vivo applications. The detailed synthesis of a bifunctional chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10,13,16-hexaazacyclohexadecane- 1,4,7,10,13,16-hexaacetic acid (HEHA-NCS) is reported. This ligand was conjugated to three monoclonal antibodies, CC49, T101, and BL-3 with chelate-to-protein ratios between 1.4 and 2. The three conjugates were radiolabeled with 225Ac, and serum stability study of the [225Ac]-BL-3-HEHA conjugate was performed.

AB - 225Ac (t(1/2) = 10 days) is an alternative α-emitter that has been proposed for radioimmunotherapy (RIT) due to its many favorable properties, such as half-life and mode of decay. The factor limiting use of 225Ac in RIT is the lack of an acceptably stable chelate for in vivo applications. Herein is described the first reported bifunctional chelate for 225Ac that has been evaluated for stability for in vivo applications. The detailed synthesis of a bifunctional chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10,13,16-hexaazacyclohexadecane- 1,4,7,10,13,16-hexaacetic acid (HEHA-NCS) is reported. This ligand was conjugated to three monoclonal antibodies, CC49, T101, and BL-3 with chelate-to-protein ratios between 1.4 and 2. The three conjugates were radiolabeled with 225Ac, and serum stability study of the [225Ac]-BL-3-HEHA conjugate was performed.

UR - http://www.scopus.com/inward/record.url?scp=0033879250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033879250&partnerID=8YFLogxK

U2 - 10.1021/bc990153f

DO - 10.1021/bc990153f

M3 - Article

C2 - 10898572

AN - SCOPUS:0033879250

VL - 11

SP - 510

EP - 519

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 4

ER -